# Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

> **NCT01074632** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

## Interventions

- **DRUG:** Lurasidone HCl

## Key facts

- **NCT ID:** NCT01074632
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074632, "Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01074632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*